

Lore Vanderbeke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4006479/publications.pdf>

Version: 2024-02-01

20
papers

1,874
citations

687220

13
h-index

794469

19
g-index

22
all docs

22
docs citations

22
times ranked

2639
citing authors

#	ARTICLE	IF	CITATIONS
1	Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. <i>Lancet Respiratory Medicine</i> , 2018, 6, 782-792.	5.2	638
2	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , 2020, 46, 1524-1535.	3.9	278
3	Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages. <i>Cell Research</i> , 2021, 31, 272-290.	5.7	229
4	Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity. <i>Nature Communications</i> , 2021, 12, 4117.	5.8	170
5	Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 471-480.	1.3	133
6	Multinational Observational Cohort Study of COVID-19-associated Pulmonary Aspergillosis. <i>Emerging Infectious Diseases</i> , 2021, 27, 2892-2898.	2.0	82
7	Increased IL-10-producing regulatory T cells are characteristic of severe cases of COVID-19. <i>Clinical and Translational Immunology</i> , 2020, 9, e1204.	1.7	59
8	Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. <i>British Journal of Haematology</i> , 2021, 192, 1100-1105.	1.2	51
9	Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. <i>Intensive Care Medicine</i> , 2021, 47, 674-686.	3.9	49
10	Clinical practices underlie COVID-19 patient respiratory microbiome composition and its interactions with the host. <i>Nature Communications</i> , 2021, 12, 6243.	5.8	42
11	Atypical response to bacterial coinfection and persistent neutrophilic bronchoalveolar inflammation distinguish critical COVID-19 from influenza. <i>JCI Insight</i> , 2022, 7, .	2.3	38
12	Kinetics of peripheral blood neutrophils in severe coronavirus disease 2019. <i>Clinical and Translational Immunology</i> , 2021, 10, e1271.	1.7	36
13	Early oseltamivir reduces risk for influenza-associated aspergillosis in a double-hit murine model. <i>Virulence</i> , 2021, 12, 2493-2508.	1.8	20
14	Neuraminidase and SIGLEC15 modulate the host defense against pulmonary aspergillosis. <i>Cell Reports Medicine</i> , 2021, 2, 100289.	3.3	15
15	High dimensional profiling identifies specific immune types along the recovery trajectories of critically ill COVID-19 patients. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 3987-4002.	2.4	13
16	Longitudinal multimodal imaging-compatible mouse model of triazole-sensitive and -resistant invasive pulmonary aspergillosis. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	1.2	12
17	Q fever: a contemporary case series from a Belgian hospital. <i>Acta Clinica Belgica</i> , 2016, 71, 290-296.	0.5	4
18	Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA-FLU study. <i>Mycoses</i> , 2022, 65, 656-660.	1.8	3

#	ARTICLE	IF	CITATIONS
19	Diagnosis of Invasive Aspergillosis in Intensive Care Unit Patients. <i>Current Fungal Infection Reports</i> , 2020, 14, 166-173.	0.9	2
20	Critical influenza and prophylactic antifungal therapy for aspergillosis: a nuanced approach to a pertinent infectious disease. <i>Intensive Care Medicine</i> , 2021, 47, 1343-1344.	3.9	0